NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 138 filers reported holding NEVRO CORP in Q3 2023. The put-call ratio across all filers is 2.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,122,052 | -29.5% | 1,046,933 | -6.8% | 0.00% | 0.0% |
| Q2 2023 | $28,544,347 | -14.4% | 1,122,909 | +21.7% | 0.00% | -50.0% |
| Q1 2023 | $33,346,134 | -49.4% | 922,438 | -44.5% | 0.00% | 0.0% |
| Q4 2022 | $65,841,178 | +72.0% | 1,662,656 | +102.4% | 0.00% | 0.0% |
| Q3 2022 | $38,282,000 | +7.7% | 821,509 | +1.3% | 0.00% | 0.0% |
| Q2 2022 | $35,540,000 | -38.9% | 810,855 | +0.8% | 0.00% | -33.3% |
| Q1 2022 | $58,184,000 | -7.3% | 804,431 | +3.9% | 0.00% | 0.0% |
| Q4 2021 | $62,793,000 | -28.5% | 774,549 | +2.7% | 0.00% | -40.0% |
| Q3 2021 | $87,812,000 | -27.8% | 754,532 | +2.8% | 0.01% | -16.7% |
| Q2 2021 | $121,641,000 | +22.8% | 733,704 | +3.3% | 0.01% | 0.0% |
| Q1 2021 | $99,080,000 | -20.3% | 710,251 | -1.1% | 0.01% | -25.0% |
| Q4 2020 | $124,370,000 | +24.4% | 718,485 | +0.1% | 0.01% | +14.3% |
| Q3 2020 | $99,974,000 | +13.8% | 717,689 | -2.4% | 0.01% | +16.7% |
| Q2 2020 | $87,882,000 | +25.4% | 735,601 | +5.0% | 0.01% | 0.0% |
| Q1 2020 | $70,063,000 | -16.1% | 700,774 | -1.4% | 0.01% | 0.0% |
| Q4 2019 | $83,514,000 | +35.8% | 710,518 | -0.7% | 0.01% | +20.0% |
| Q3 2019 | $61,492,000 | +27.3% | 715,275 | -4.0% | 0.01% | +25.0% |
| Q2 2019 | $48,294,000 | -5.3% | 744,938 | -8.7% | 0.00% | 0.0% |
| Q1 2019 | $50,983,000 | +72.3% | 815,603 | +7.2% | 0.00% | +33.3% |
| Q4 2018 | $29,597,000 | -33.1% | 761,046 | -2.0% | 0.00% | 0.0% |
| Q3 2018 | $44,250,000 | -14.2% | 776,255 | +20.2% | 0.00% | -25.0% |
| Q2 2018 | $51,558,000 | +1.8% | 645,622 | +10.5% | 0.00% | 0.0% |
| Q1 2018 | $50,643,000 | +24.3% | 584,322 | -1.0% | 0.00% | +33.3% |
| Q4 2017 | $40,748,000 | -18.9% | 590,215 | +6.8% | 0.00% | -25.0% |
| Q3 2017 | $50,220,000 | +25.3% | 552,633 | +2.6% | 0.00% | 0.0% |
| Q2 2017 | $40,082,000 | -7.3% | 538,517 | +16.7% | 0.00% | 0.0% |
| Q1 2017 | $43,222,000 | +35.3% | 461,309 | +4.9% | 0.00% | +33.3% |
| Q4 2016 | $31,955,000 | -26.6% | 439,751 | +5.5% | 0.00% | -25.0% |
| Q3 2016 | $43,518,000 | +54.8% | 416,899 | +9.4% | 0.00% | +33.3% |
| Q2 2016 | $28,106,000 | +78.0% | 380,996 | +35.8% | 0.00% | +50.0% |
| Q1 2016 | $15,786,000 | -12.8% | 280,583 | +4.6% | 0.00% | 0.0% |
| Q4 2015 | $18,110,000 | +57.7% | 268,268 | +8.4% | 0.00% | +100.0% |
| Q3 2015 | $11,486,000 | +10.1% | 247,490 | +27.6% | 0.00% | 0.0% |
| Q2 2015 | $10,432,000 | +118.9% | 194,022 | +95.3% | 0.00% | – |
| Q1 2015 | $4,765,000 | +86.4% | 99,358 | +50.3% | 0.00% | – |
| Q4 2014 | $2,557,000 | – | 66,088 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |